argenx NV ADR

Yahoo Finance • 4 days ago

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

argenx SE VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative Patients t... Full story

Yahoo Finance • 6 days ago

Zoetis Crashes As Even Slashed Guidance Appears To Be A 'Heavy Lift'

Zoetis stock crashed early Thursday after the pet health company cut its outlook on a sales and earnings miss. Continue Reading... Full story

Yahoo Finance • 6 days ago

argenx SE GAAP EPS of $5.52 beats by $0.31, revenue of $1.3B misses by $10M

* argenx SE press release [https://seekingalpha.com/pr/20504728-argenx-reports-first-quarter-2026-financial-results-and-provides-business-update] (ARGX [https://seekingalpha.com/symbol/ARGX]): Q1 GAAP EPS of $5.52 beats by $0.31. * Rev... Full story

Yahoo Finance • 6 days ago

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune... Full story

Yahoo Finance • 9 days ago

Here’s Why Argenx SE (ARGX) Slipped in Q1

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Sha... Full story

Yahoo Finance • 11 days ago

Argenx (ARGX) Outlook Improves on Autoimmune Pipeline Expansion

Argenx SE (NASDAQ:ARGX) ranks among the most profitable biotech stocks to buy now. On April 14, TD Cowen maintained its Buy rating and $1,146 price target for Argenx SE (NASDAQ:ARGX), citing a quarterly monitoring poll that indicated first... Full story

Yahoo Finance • 22 days ago

European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were falling sharply late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 25 days ago

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OCULUS, and Jr study results build on VYV... Full story

Yahoo Finance • 28 days ago

European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were heading lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

Key Points RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW... Full story

Yahoo Finance • 2 months ago

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

RTW Investments disclosed a significant buy of Cogent Biosciences(NASDAQ:COGT) in its February 17, 2026, SEC filing, adding 4,124,755 shares in a trade estimated at $115.95 million based on quarterly average pricing. What happened Accord... Full story

Yahoo Finance • 2 months ago

Analysts Highlight Vyvgart Expansion as Major Growth Driver for Argenx (ARGX)

Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while... Full story

Yahoo Finance • 2 months ago

Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics

Unnatural Products Inc. Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investors SANTA CRUZ, Calif., March 16... Full story

Yahoo Finance • 2 months ago

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectab... Full story

Yahoo Finance • 2 months ago

Oversold Conditions For argenx (ARGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 2 months ago

Argenx Eyes Ocular Myasthenia Gravis To Deepen VYVGART Growth Story

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. argenx (ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gra... Full story

Yahoo Finance • 2 months ago

argenex Q4 Earnings Call Highlights

argenex logo 3 Healthcare Pathbreakers With Long-Term Tailwinds argenx (NASDAQ:ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, an... Full story

Yahoo Finance • 2 months ago

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

Study met primary endpoint (p-value = 0.012) First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission t... Full story

Yahoo Finance • 3 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VI... Full story

Yahoo Finance • 3 months ago

Artisan Mid Cap Fund Maintains Its Confidence in Argenx’s (ARGX) VYVGART

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Fund”.  A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise cha... Full story